newsBMS, Pfizer and Portola team up to bring andexanet alfa to Japan1 February 2016 | By Victoria WhiteAndexanet alfa is designed to reverse the anticoagulant activity of Factor Xa inhibitors, including Eliquis (apixaban)...
newsResults of Phase 3 study of andexanet alfa presented at ISTH 201522 June 2015 | By Victoria WhiteFull results from the second part of a Phase 3 trial evaluating the safety and efficacy of andexanet alfa as a reversal agent of Eliquis have been announced...
newsPortola, Bristol-Myers Squibb and Pfizer announce statistically significant results from the first part of the Phase 3 ANNEXA™-A studies of investigational Andexanet Alfa with Eliquis (apixaban)18 November 2014 | By Bristol-Myers Squibb CompanyBristol-Myers Squibb Company and Pfizer Inc. announced results from the first part of the Phase 3 ANNEXA™-A (Andexanet Alfa a Novel Antidote to the Anticoagulant Effects of fXA Inhibitors – Apixaban) studies...